Subventions financées

A common feature in almost all ALS cases is the build up of a protein called TDP-43 in the brain and spinal cord.

Glioblastoma (GBM) is a common and deadly brain cancer in adults.

We are studying a type of brain tumour called glioblastoma (GBM), which is often fatal despite current treatments.

Led by Dr. Elie Haddad from CHU Sainte-Justine in collaboration with Immugenia, this project includes an inter-provincial research collaboration

Kendra Loedige, a Master’s student at the University of Western Ontario, aims to understand how genetic variations in CADM2 contributes to mental illness and substance use disorders by identifying specific genes that could serve as therapeutic targets.

The immune system is responsible for protecting the body against diseases, but it can also play a role in tumor formation.

Melanoma brain metastases (MBMs) are a serious issue affecting up to half of all patients with stage IV melanoma, typically leading to a poor outlook.

Led by Dr. Jocelyn Faubert from the Université de Montréal in collaboration with Neurotracker Athletics Inc., this project includes an inter-provincial research collaboration with Prof. Brian Christie and Prof. Jodie Gawryluk from the University of Victoria.

Endogenous retrovirus-K (ERVK) is a genomic viral symbiont that contributes towards ALS neuropathology.

The proposed research project aims to study the differences in brain function behaviour between male and female university athletes who have experienced a concussion.